 The European Commission has approved Amicus Therapeutics Inc NASDAQ: FOLD Galafold migalastat for use in adolescents with Fabry disease who have an amenable mutation. Galafold is already approved in the U.S., EU, and Japan for adults who have an amenable variant or mutation. 